{"transactions":[{"id":711504,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-07-10T22:54:36.000Z","date":"2026-07-10","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":6.24,"value":1248000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":936410,"source":{"system":"sec-edgar","filing":"0001665124-26-000013","document":"form4-07102026_100732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000013/form4-07102026_100732.xml","form_type":"4"}},{"id":741731,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-06-11T20:05:26.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":77500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":77500,"derivative":{"exercise_price":6.61,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":77500},"source":{"system":"sec-edgar","filing":"0001193125-26-267504","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526267504/ownership.xml","form_type":"4"}},{"id":810009,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-13T20:33:58.000Z","date":"2026-04-10","kind":"exercise","planned":true,"acquired":false,"shares":19021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":455920,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":19021},"source":{"system":"sec-edgar","filing":"0001665124-26-000011","document":"form4-04132026_080454.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000011/form4-04132026_080454.xml","form_type":"4"}},{"id":810008,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-04-13T20:33:58.000Z","date":"2026-04-10","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":4.46,"value":892000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.335 to $4.625 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1136410,"source":{"system":"sec-edgar","filing":"0001665124-26-000011","document":"form4-04132026_080454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000011/form4-04132026_080454.xml","form_type":"4"}},{"id":810007,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-04-13T20:33:58.000Z","date":"2026-04-10","kind":"exercise","planned":true,"acquired":true,"shares":19021,"price":1.71,"value":32525.91,"ownership":{"direct":true},"balance_after":1336410,"source":{"system":"sec-edgar","filing":"0001665124-26-000011","document":"form4-04132026_080454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000011/form4-04132026_080454.xml","form_type":"4"}},{"id":930580,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:16.000Z","date":"2026-01-26","kind":"sale","planned":false,"acquired":false,"shares":26918,"price":4.61,"value":124091.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive."}],"balance_after":1317389,"source":{"system":"sec-edgar","filing":"0001665124-26-000008","document":"form4-01272026_040105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000008/form4-01272026_040105.xml","form_type":"4"}},{"id":930579,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:16.000Z","date":"2026-01-23","kind":"sale","planned":false,"acquired":false,"shares":89132,"price":4.75,"value":423377.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":1344307,"source":{"system":"sec-edgar","filing":"0001665124-26-000008","document":"form4-01272026_040105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000008/form4-01272026_040105.xml","form_type":"4"}},{"id":939686,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"grant","planned":true,"acquired":true,"shares":274000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":274000,"derivative":{"exercise_price":4.86,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":274000},"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":939685,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"exercise","planned":true,"acquired":false,"shares":88676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":474941,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":88676},"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":939684,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"exercise","planned":true,"acquired":false,"shares":111324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":111359,"derivative":{"exercise_price":0.6989,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":111324},"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":939683,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"grant","planned":true,"acquired":true,"shares":427000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1433439,"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":939682,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":4.71,"value":942000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1006439,"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":939681,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"exercise","planned":true,"acquired":true,"shares":88676,"price":1.71,"value":151635.96,"ownership":{"direct":true},"balance_after":1206439,"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":939680,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2026-01-14T21:45:07.000Z","date":"2026-01-12","kind":"exercise","planned":true,"acquired":true,"shares":111324,"price":0.6989,"value":77804.3436,"ownership":{"direct":true},"balance_after":1117763,"source":{"system":"sec-edgar","filing":"0001665124-26-000002","document":"form4-01142026_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512426000002/form4-01142026_040101.xml","form_type":"4"}},{"id":985787,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-02T01:58:44.000Z","date":"2025-12-01","kind":"exercise","planned":false,"acquired":false,"shares":260047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":563617,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":260047},"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985786,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-02T01:58:44.000Z","date":"2025-11-28","kind":"exercise","planned":false,"acquired":false,"shares":39953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":823664,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":39953},"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985785,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-02T01:58:44.000Z","date":"2025-11-28","kind":"exercise","planned":false,"acquired":false,"shares":70172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":222683,"derivative":{"exercise_price":0.6989,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":70172},"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985784,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-12-02T01:58:44.000Z","date":"2025-12-01","kind":"sale","planned":false,"acquired":false,"shares":260047,"price":4.51,"value":1172811.97,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive."}],"balance_after":1006439,"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985783,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-12-02T01:58:44.000Z","date":"2025-12-01","kind":"exercise","planned":false,"acquired":true,"shares":260047,"price":1.71,"value":444680.37,"ownership":{"direct":true},"balance_after":1266486,"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985782,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-12-02T01:58:44.000Z","date":"2025-11-28","kind":"sale","planned":false,"acquired":false,"shares":110125,"price":4.75,"value":523093.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2)."}],"balance_after":1006439,"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985781,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-12-02T01:58:44.000Z","date":"2025-11-28","kind":"exercise","planned":false,"acquired":true,"shares":39953,"price":1.71,"value":68319.63,"ownership":{"direct":true},"balance_after":1116564,"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":985780,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-12-02T01:58:44.000Z","date":"2025-11-28","kind":"exercise","planned":false,"acquired":true,"shares":70172,"price":0.6989,"value":49043.2108,"ownership":{"direct":true},"balance_after":1076611,"source":{"system":"sec-edgar","filing":"0001665124-25-000003","document":"form4-12022025_011240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000166512425000003/form4-12022025_011240.xml","form_type":"4"}},{"id":1042244,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-12T20:15:25.000Z","date":"2025-09-10","kind":"exercise","planned":true,"acquired":false,"shares":41150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":292855,"derivative":{"exercise_price":0.6989,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":41150},"source":{"system":"sec-edgar","filing":"0001415889-25-024369","document":"form4-09122025_040917.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925024369/form4-09122025_040917.xml","form_type":"4"}},{"id":1042243,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-09-12T20:15:25.000Z","date":"2025-09-10","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":3.23,"value":646000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.165 to $3.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1006439,"source":{"system":"sec-edgar","filing":"0001415889-25-024369","document":"form4-09122025_040917.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925024369/form4-09122025_040917.xml","form_type":"4"}},{"id":1042242,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-09-12T20:15:25.000Z","date":"2025-09-10","kind":"exercise","planned":true,"acquired":true,"shares":41150,"price":0.6989,"value":28759.735,"ownership":{"direct":true},"balance_after":1206439,"source":{"system":"sec-edgar","filing":"0001415889-25-024369","document":"form4-09122025_040917.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925024369/form4-09122025_040917.xml","form_type":"4"}},{"id":1058792,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-08-22T20:15:17.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":57054,"price":2.85,"value":162603.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1165289,"source":{"system":"sec-edgar","filing":"0001415889-25-022750","document":"form4-08222025_040806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925022750/form4-08222025_040806.xml","form_type":"4"}},{"id":1111736,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-13T20:25:48.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":77500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":77500,"derivative":{"exercise_price":4.58,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":77500},"source":{"system":"sec-edgar","filing":"0000950170-25-086238","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017025086238/ownership.xml","form_type":"4"}},{"id":1317455,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-03T22:36:40.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":324500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2026 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":324500,"derivative":{"exercise_price":1.85,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":324500},"source":{"system":"sec-edgar","filing":"0001415889-25-000597","document":"form4-01032025_100136.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925000597/form4-01032025_100136.xml","form_type":"4"}},{"id":1317454,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2025-01-03T22:36:40.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":324500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSU grant was approved by the Issuer's compensation committee of the board of directors and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares\navailable for issuance under the 2020 Stock Incentive Plan. The RSUs will vest in four equal annual installments beginning on January 2, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1222343,"source":{"system":"sec-edgar","filing":"0001415889-25-000597","document":"form4-01032025_100136.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925000597/form4-01032025_100136.xml","form_type":"4"}},{"id":1480767,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-06-13T20:08:01.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":34400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2024 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":34400,"derivative":{"exercise_price":7.51,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":34400},"source":{"system":"sec-edgar","filing":"0000950170-24-072998","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017024072998/ownership.xml","form_type":"4"}},{"id":1689763,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-04T21:42:30.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":863617,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":863617,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":863617},"source":{"system":"sec-edgar","filing":"0001209191-24-000809","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919124000809/doc4.xml","form_type":"4"}},{"id":1689762,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2024-01-04T21:42:30.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":863617,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":897843,"source":{"system":"sec-edgar","filing":"0001209191-24-000809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919124000809/doc4.xml","form_type":"4"}},{"id":1708250,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-12-18T21:47:23.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":334005,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":334005,"derivative":{"exercise_price":0.6989,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":334005},"source":{"system":"sec-edgar","filing":"0001209191-23-058973","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123058973/doc4.xml","form_type":"4"}},{"id":1862423,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-09T01:19:49.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":9650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":9650,"derivative":{"exercise_price":6.37,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":9650},"source":{"system":"sec-edgar","filing":"0000899243-23-015002","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924323015002/doc4.xml","form_type":"4"}},{"id":1887781,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Common Stock","published_at":"2023-05-18T20:44:26.000Z","date":"2023-05-16","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":0.68,"value":3400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.682 to $0.6879 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":34226,"source":{"system":"sec-edgar","filing":"0001209191-23-030661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123030661/doc4.xml","form_type":"4"}},{"id":2070863,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Head of R&D"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-04T21:51:02.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":790093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the option shall vest and become exercisable on December 16, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":790093,"derivative":{"exercise_price":2.26,"expiration_date":"2032-12-30","underlying":"Common Stock","underlying_shares":790093},"source":{"system":"sec-edgar","filing":"0001209191-23-001019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123001019/doc4.xml","form_type":"4"}},{"id":2085160,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-12-15T23:07:44.000Z","date":"2022-12-13","kind":"grant","acquired":true,"shares":9650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 13, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":9650,"derivative":{"exercise_price":6.47,"expiration_date":"2032-12-13","underlying":"Common Stock","underlying_shares":9650},"source":{"system":"sec-edgar","filing":"0000899243-22-038681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924322038681/doc4.xml","form_type":"4"}},{"id":2224675,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-22T20:39:31.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 17, 2023 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director though the applicable vesting date."}],"balance_after":15500,"derivative":{"exercise_price":2.81,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-22-038690","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122038690/doc4.xml","form_type":"4"}},{"id":2237814,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-06-09T21:11:27.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":51000,"derivative":{"exercise_price":0.625,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0001209191-22-035461","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000120919122035461/doc4.xml","form_type":"4"}},{"id":2415236,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-03T14:21:09.000Z","date":"2022-02-02","kind":"purchase","acquired":true,"shares":10000,"price":8.01,"value":80100.0,"ownership":{"direct":true},"balance_after":29226,"source":{"system":"sec-edgar","filing":"0001209191-22-006652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122006652/doc4.xml","form_type":"4"}},{"id":2662325,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-21T21:04:19.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 17, 2022 or the next annual stockholders meeting, subject to continued service as a director though the applicable vesting date."}],"balance_after":15500,"derivative":{"exercise_price":25.04,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-21-042110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121042110/doc4.xml","form_type":"4"}},{"id":2661166,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-06-21T20:00:17.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":30000,"derivative":{"exercise_price":3.94,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-041934","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000120919121041934/doc4.xml","form_type":"4"}},{"id":3020352,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-30T20:37:58.000Z","date":"2020-09-28","kind":"exercise","acquired":false,"shares":17647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-1.0895 basis for no additional consideration, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-1.0895 basis for no additional consideration, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-1.0895 basis for no additional consideration, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19226},"source":{"system":"sec-edgar","filing":"0001209191-20-052460","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052460/doc4.xml","form_type":"4"}},{"id":3020351,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-30T20:37:58.000Z","date":"2020-09-28","kind":"exercise","acquired":true,"shares":19226,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-1.0895 basis for no additional consideration, and had no expiration date."}],"balance_after":19226,"source":{"system":"sec-edgar","filing":"0001209191-20-052460","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052460/doc4.xml","form_type":"4"}},{"id":3022673,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-09-25T21:12:29.000Z","date":"2020-09-23","kind":"grant","acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option vest in 36 equal monthly installments, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":31000,"derivative":{"exercise_price":20,"expiration_date":"2030-09-23","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001209191-20-052114","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052114/doc4.xml","form_type":"4"}},{"id":3105622,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-06-18T20:18:14.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 16, 2020 to members of the Clinical Committee of the Board of Directors and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"This option was granted on June 16, 2020 to members of the Clinical Committee of the Board of Directors and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":10000,"derivative":{"exercise_price":3.03,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-037576","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000120919120037576/doc4.xml","form_type":"4"}},{"id":3105621,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-06-18T20:18:14.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 16, 2020 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":30000,"derivative":{"exercise_price":3.03,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-037576","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000120919120037576/doc4.xml","form_type":"4"}},{"id":3454317,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-29T20:30:08.000Z","date":"2019-07-25","kind":"grant","acquired":true,"shares":32258,"price":4.65,"value":149999.7,"ownership":{"direct":true},"balance_after":34258,"source":{"system":"sec-edgar","filing":"0001209191-19-043487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000120919119043487/doc4.xml","form_type":"4"}},{"id":3489725,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-06-14T20:15:08.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 13, 2019 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":10000,"derivative":{"exercise_price":5.26,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-037123","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000120919119037123/doc4.xml","form_type":"4"}},{"id":3729327,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-12-17T21:06:22.000Z","date":"2018-12-13","kind":"grant","acquired":true,"shares":17240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 13, 2018 and vests as to one-third of the total number of shares on each of September 12, 2019, September 12, 2020, and September 12, 2021, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":17240,"derivative":{"exercise_price":23.58,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":17240},"source":{"system":"sec-edgar","filing":"0000899243-18-031204","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924318031204/doc4.xml","form_type":"4"}},{"id":3817076,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option\n(Right to Buy)","published_at":"2018-09-13T18:50:20.000Z","date":"2018-09-12","kind":"grant","acquired":true,"shares":2760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on September 12, 2018 and vests as to one-third of the total number of shares on each of the next three anniversaries of the grant date."}],"balance_after":2760,"derivative":{"exercise_price":50.65,"expiration_date":"2028-09-12","underlying":"Common Stock","underlying_shares":2760},"source":{"system":"sec-edgar","filing":"0000899243-18-024397","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924318024397/doc4.xml","form_type":"4"}},{"id":3932996,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Performance Stock Units (Right to Buy)","published_at":"2018-05-15T12:37:42.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":9906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On March 20, 2017, the Reporting Person was awarded a performance stock unit (the \"PSU\") equal to 9,906 shares of Common Stock, subject to the achievement of certain regulatory and manufacturing milestones. On May 15, 2018, in connection with the closing of the transactions contemplated by the Merger Agreement, all applicable performance milestones were satisfied."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, each outstanding PSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock subject to the PSU."}],"balance_after":0,"derivative":{"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":9906},"source":{"system":"sec-edgar","filing":"0001209191-18-030126","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030126/doc4.xml","form_type":"4"}},{"id":3932995,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Performance Stock Units   (Right to Buy)","published_at":"2018-05-15T12:37:42.000Z","date":"2018-05-15","kind":"grant","acquired":true,"shares":9906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On March 20, 2017, the Reporting Person was awarded a performance stock unit (the \"PSU\") equal to 9,906 shares of Common Stock, subject to the achievement of certain regulatory and manufacturing milestones. On May 15, 2018, in connection with the closing of the transactions contemplated by the Merger Agreement, all applicable performance milestones were satisfied."},{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 20, 2017, the Reporting Person was awarded a performance stock unit (the \"PSU\") equal to 9,906 shares of Common Stock, subject to the achievement of certain regulatory and manufacturing milestones. On May 15, 2018, in connection with the closing of the transactions contemplated by the Merger Agreement, all applicable performance milestones were satisfied."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately exercisable."}],"balance_after":9906,"derivative":{"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":9906},"source":{"system":"sec-edgar","filing":"0001209191-18-030126","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030126/doc4.xml","form_type":"4"}},{"id":3932994,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:37:42.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":133.8,"expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-030126","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030126/doc4.xml","form_type":"4"}},{"id":3932993,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:37:42.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":25200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":77.24,"expiration_date":"2027-05-10","underlying":"Common Stock","underlying_shares":25200},"source":{"system":"sec-edgar","filing":"0001209191-18-030126","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030126/doc4.xml","form_type":"4"}},{"id":3932992,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:37:42.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":37750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":42.61,"expiration_date":"2026-06-20","underlying":"Common Stock","underlying_shares":37750},"source":{"system":"sec-edgar","filing":"0001209191-18-030126","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030126/doc4.xml","form_type":"4"}},{"id":3932991,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:37:42.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":178494,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":18.47,"expiration_date":"2025-09-14","underlying":"Common Stock","underlying_shares":178494},"source":{"system":"sec-edgar","filing":"0001209191-18-030126","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030126/doc4.xml","form_type":"4"}},{"id":3932990,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-05-15T12:37:42.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":3800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 3,800 shares underlying Restricted Stock Units (the \"RSUs\"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-030126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030126/doc4.xml","form_type":"4"}},{"id":3981977,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-27T17:33:05.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable as to 25% of the shares underlying the option on March 13, 2019; the remaining shares shall vest in 36 equal monthly installments beginning on April 13, 2019, subject to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":15000,"derivative":{"exercise_price":133.8,"expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-021792","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118021792/doc4.xml","form_type":"4"}},{"id":3981976,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-27T17:33:05.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":3800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest in 3 equal annual installments beginning on March 13, 2019, such that the restricted stock award will be fully vested on March 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest in 3 equal annual installments beginning on March 13, 2019, such that the restricted stock award will be fully vested on March 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":3800,"source":{"system":"sec-edgar","filing":"0001209191-18-021792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118021792/doc4.xml","form_type":"4"}},{"id":4015492,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-05T16:36:40.000Z","date":"2018-02-01","kind":"exercise","acquired":false,"shares":1780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":178494,"derivative":{"exercise_price":18.47,"expiration_date":"2025-10-13","underlying":"Common Stock","underlying_shares":1780},"source":{"system":"sec-edgar","filing":"0001209191-18-016481","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118016481/doc4.xml","form_type":"4"}},{"id":4015491,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-05T16:36:40.000Z","date":"2018-03-01","kind":"sale","acquired":false,"shares":50,"price":128.91,"value":6445.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.91 to $128.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-016481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118016481/doc4.xml","form_type":"4"}},{"id":4015490,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-05T16:36:40.000Z","date":"2018-03-01","kind":"sale","acquired":false,"shares":408,"price":127.99,"value":52219.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.59 to $128.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4."}],"balance_after":50,"source":{"system":"sec-edgar","filing":"0001209191-18-016481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118016481/doc4.xml","form_type":"4"}},{"id":4015489,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-05T16:36:40.000Z","date":"2018-03-01","kind":"sale","acquired":false,"shares":504,"price":126.95,"value":63982.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.52 to $127.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4."}],"balance_after":458,"source":{"system":"sec-edgar","filing":"0001209191-18-016481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118016481/doc4.xml","form_type":"4"}},{"id":4015488,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-05T16:36:40.000Z","date":"2018-03-01","kind":"sale","acquired":false,"shares":449,"price":125.72,"value":56448.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.19 to $126.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4."}],"balance_after":962,"source":{"system":"sec-edgar","filing":"0001209191-18-016481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118016481/doc4.xml","form_type":"4"}},{"id":4015487,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-05T16:36:40.000Z","date":"2018-03-01","kind":"sale","acquired":false,"shares":175,"price":124.29,"value":21750.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.08 to $124.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4."}],"balance_after":1411,"source":{"system":"sec-edgar","filing":"0001209191-18-016481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118016481/doc4.xml","form_type":"4"}},{"id":4015486,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-05T16:36:40.000Z","date":"2018-03-01","kind":"sale","acquired":false,"shares":120,"price":123.16,"value":14779.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.51 to $123.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":1586,"source":{"system":"sec-edgar","filing":"0001209191-18-016481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118016481/doc4.xml","form_type":"4"}},{"id":4015485,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-05T16:36:40.000Z","date":"2018-03-01","kind":"sale","acquired":false,"shares":74,"price":121.51,"value":8991.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.50 to $121.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":1706,"source":{"system":"sec-edgar","filing":"0001209191-18-016481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118016481/doc4.xml","form_type":"4"}},{"id":4015484,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-05T16:36:40.000Z","date":"2018-03-01","kind":"exercise","acquired":true,"shares":1780,"price":18.47,"value":32876.6,"ownership":{"direct":true},"balance_after":1780,"source":{"system":"sec-edgar","filing":"0001209191-18-016481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118016481/doc4.xml","form_type":"4"}},{"id":4076398,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-02-05T16:58:02.000Z","date":"2018-02-01","kind":"exercise","acquired":false,"shares":1780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":180274,"derivative":{"exercise_price":18.47,"expiration_date":"2025-10-13","underlying":"Common Stock","underlying_shares":1780},"source":{"system":"sec-edgar","filing":"0001209191-18-007554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118007554/doc4.xml","form_type":"4"}},{"id":4076397,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-02-05T16:58:02.000Z","date":"2018-02-01","kind":"sale","acquired":false,"shares":17,"price":122.83,"value":2088.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-007554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118007554/doc4.xml","form_type":"4"}},{"id":4076396,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-02-05T16:58:02.000Z","date":"2018-02-01","kind":"sale","acquired":false,"shares":258,"price":120.79,"value":31163.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.74 to $120.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4."}],"balance_after":17,"source":{"system":"sec-edgar","filing":"0001209191-18-007554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118007554/doc4.xml","form_type":"4"}},{"id":4076395,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-02-05T16:58:02.000Z","date":"2018-02-01","kind":"sale","acquired":false,"shares":3,"price":118.96,"value":356.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."}],"balance_after":275,"source":{"system":"sec-edgar","filing":"0001209191-18-007554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118007554/doc4.xml","form_type":"4"}},{"id":4076394,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-02-05T16:58:02.000Z","date":"2018-02-01","kind":"sale","acquired":false,"shares":501,"price":118.01,"value":59123.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.63 to $118.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":278,"source":{"system":"sec-edgar","filing":"0001209191-18-007554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118007554/doc4.xml","form_type":"4"}},{"id":4076393,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-02-05T16:58:02.000Z","date":"2018-02-01","kind":"sale","acquired":false,"shares":1001,"price":117.12,"value":117237.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.63 to $117.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":779,"source":{"system":"sec-edgar","filing":"0001209191-18-007554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118007554/doc4.xml","form_type":"4"}},{"id":4076392,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-02-05T16:58:02.000Z","date":"2018-02-01","kind":"exercise","acquired":true,"shares":1780,"price":18.47,"value":32876.6,"ownership":{"direct":true},"balance_after":1780,"source":{"system":"sec-edgar","filing":"0001209191-18-007554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118007554/doc4.xml","form_type":"4"}},{"id":4107589,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-01-04T17:38:05.000Z","date":"2018-01-02","kind":"exercise","acquired":false,"shares":1780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":182054,"derivative":{"exercise_price":18.47,"expiration_date":"2025-10-13","underlying":"Common Stock","underlying_shares":1780},"source":{"system":"sec-edgar","filing":"0001209191-18-002110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118002110/doc4.xml","form_type":"4"}},{"id":4107588,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-01-04T17:38:05.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":684,"price":110.21,"value":75383.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.89 to $110.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-002110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118002110/doc4.xml","form_type":"4"}},{"id":4107587,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-01-04T17:38:05.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":1096,"price":109.42,"value":119924.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.85 to $109.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":684,"source":{"system":"sec-edgar","filing":"0001209191-18-002110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118002110/doc4.xml","form_type":"4"}},{"id":4107586,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-01-04T17:38:05.000Z","date":"2018-01-02","kind":"exercise","acquired":true,"shares":1780,"price":18.47,"value":32876.6,"ownership":{"direct":true},"balance_after":1780,"source":{"system":"sec-edgar","filing":"0001209191-18-002110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118002110/doc4.xml","form_type":"4"}},{"id":4142112,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-12-05T18:32:33.000Z","date":"2017-12-01","kind":"exercise","acquired":false,"shares":1780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":183834,"derivative":{"exercise_price":18.47,"expiration_date":"2025-10-13","underlying":"Common Stock","underlying_shares":1780},"source":{"system":"sec-edgar","filing":"0001209191-17-064044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117064044/doc4.xml","form_type":"4"}},{"id":4142111,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-12-05T18:32:33.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":135,"price":95.81,"value":12934.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.55 to $95.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-064044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117064044/doc4.xml","form_type":"4"}},{"id":4142110,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-12-05T18:32:33.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":1327,"price":94.92,"value":125958.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.37 to $95.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":135,"source":{"system":"sec-edgar","filing":"0001209191-17-064044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117064044/doc4.xml","form_type":"4"}},{"id":4142109,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-12-05T18:32:33.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":318,"price":93.72,"value":29802.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.31 to $94.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":1462,"source":{"system":"sec-edgar","filing":"0001209191-17-064044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117064044/doc4.xml","form_type":"4"}},{"id":4142108,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-12-05T18:32:33.000Z","date":"2017-12-01","kind":"exercise","acquired":true,"shares":1780,"price":18.47,"value":32876.6,"ownership":{"direct":true},"balance_after":1780,"source":{"system":"sec-edgar","filing":"0001209191-17-064044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117064044/doc4.xml","form_type":"4"}},{"id":4172827,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-11-03T17:01:34.000Z","date":"2017-11-01","kind":"exercise","acquired":false,"shares":1780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":185614,"derivative":{"exercise_price":18.47,"expiration_date":"2025-10-13","underlying":"Common Stock","underlying_shares":1780},"source":{"system":"sec-edgar","filing":"0001209191-17-059215","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117059215/doc4.xml","form_type":"4"}},{"id":4172826,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-11-03T17:01:34.000Z","date":"2017-11-01","kind":"sale","acquired":false,"shares":70,"price":106.26,"value":7438.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.26 to $106.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-059215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117059215/doc4.xml","form_type":"4"}},{"id":4172825,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-11-03T17:01:34.000Z","date":"2017-11-01","kind":"sale","acquired":false,"shares":205,"price":105.02,"value":21529.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.95 to $105.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4."}],"balance_after":70,"source":{"system":"sec-edgar","filing":"0001209191-17-059215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117059215/doc4.xml","form_type":"4"}},{"id":4172824,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-11-03T17:01:34.000Z","date":"2017-11-01","kind":"sale","acquired":false,"shares":149,"price":104.06,"value":15504.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.63 to $104.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4."}],"balance_after":275,"source":{"system":"sec-edgar","filing":"0001209191-17-059215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117059215/doc4.xml","form_type":"4"}},{"id":4172823,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-11-03T17:01:34.000Z","date":"2017-11-01","kind":"sale","acquired":false,"shares":42,"price":102,"value":4284.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."}],"balance_after":424,"source":{"system":"sec-edgar","filing":"0001209191-17-059215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117059215/doc4.xml","form_type":"4"}},{"id":4172822,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-11-03T17:01:34.000Z","date":"2017-11-01","kind":"sale","acquired":false,"shares":631,"price":100.7,"value":63541.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.44 to $101.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4."}],"balance_after":466,"source":{"system":"sec-edgar","filing":"0001209191-17-059215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117059215/doc4.xml","form_type":"4"}},{"id":4172821,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-11-03T17:01:34.000Z","date":"2017-11-01","kind":"sale","acquired":false,"shares":431,"price":100.05,"value":43121.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.36 to $100.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":1097,"source":{"system":"sec-edgar","filing":"0001209191-17-059215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117059215/doc4.xml","form_type":"4"}},{"id":4172820,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-11-03T17:01:34.000Z","date":"2017-11-01","kind":"sale","acquired":false,"shares":252,"price":98.51,"value":24824.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.29 to $98.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":1528,"source":{"system":"sec-edgar","filing":"0001209191-17-059215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117059215/doc4.xml","form_type":"4"}},{"id":4172819,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-11-03T17:01:34.000Z","date":"2017-11-01","kind":"exercise","acquired":true,"shares":1780,"price":18.47,"value":32876.6,"ownership":{"direct":true},"balance_after":1780,"source":{"system":"sec-edgar","filing":"0001209191-17-059215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117059215/doc4.xml","form_type":"4"}},{"id":4194772,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-03T17:05:06.000Z","date":"2017-10-02","kind":"exercise","acquired":false,"shares":1780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":187394,"derivative":{"exercise_price":18.47,"expiration_date":"2025-10-13","underlying":"Common Stock","underlying_shares":1780},"source":{"system":"sec-edgar","filing":"0001209191-17-055231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117055231/doc4.xml","form_type":"4"}},{"id":4194771,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-10-03T17:05:06.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":170,"price":99.26,"value":16874.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.19 to $99.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-055231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117055231/doc4.xml","form_type":"4"}},{"id":4194770,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-10-03T17:05:06.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":385,"price":98.77,"value":38026.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.10 to $98.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4."}],"balance_after":170,"source":{"system":"sec-edgar","filing":"0001209191-17-055231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117055231/doc4.xml","form_type":"4"}},{"id":4194769,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-10-03T17:05:06.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":587,"price":96.98,"value":56927.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.64 to $97.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":555,"source":{"system":"sec-edgar","filing":"0001209191-17-055231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117055231/doc4.xml","form_type":"4"}},{"id":4194768,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-10-03T17:05:06.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":638,"price":96.05,"value":61279.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.56 to $96.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":1142,"source":{"system":"sec-edgar","filing":"0001209191-17-055231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117055231/doc4.xml","form_type":"4"}},{"id":4194767,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":31122,"kind":"person","name":"Nagendran Sukumar","position":1,"cik":"0001665124","reported_name":"Nagendran Sukumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-10-03T17:05:06.000Z","date":"2017-10-02","kind":"exercise","acquired":true,"shares":1780,"price":18.47,"value":32876.6,"ownership":{"direct":true},"balance_after":1780,"source":{"system":"sec-edgar","filing":"0001209191-17-055231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117055231/doc4.xml","form_type":"4"}}],"next_cursor":"2017-10-03T17:05:06.000000Z,4194767"}